Create an alert
Stocks and Shares ISAGensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Gensight Biologics SA (SIGHT) EUR0.025
Sell:€0.10Buy:€0.11
€0.01
(6.67%)
Prices delayed by at least 15 minutes
- This stock can be held in a
Sell:€0.10
Buy:€0.11
Change:€0.01
(6.67%)
€0.01
(6.67%)Prices delayed by at least 15 minutes
Sell:€0.10
Buy:€0.11
Change:€0.01
(6.67%)
€0.01
(6.67%)Prices delayed by at least 15 minutes
Company Information
About this company
Key people
Laurence Rodriguez
Chief Executive Officer
Jose-Alain Sahel
Founder, Director
Connie Cepko
Founder
Serge Picaud
Founder
Botond Roska
Founder
Luk H. Vandenberghe
Founder
Jan Eryk Umiastowski
Chief Financial Officer
Julio Benedicto
Senior Vice President - Strategy and Operations
Scott Jeffers
Chief Technology Officer
Magali Gibou
Vice President - Regulatory and Quality
Michael S. Wyzga
Chairman of the Board
Cedric Moreau
Director, Representative of Sofinnova Partners
Elsy Boglioli
Independent Director
Francoise de Craecker
Independent Director
Maritza C. Mcintyre
Independent Director
Click to see more
Key facts
- Shares in issue131.47m
- EPICSIGHT
- ISINFR0013183985
- LocationFrance
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap€21.71m
- Employees13
- ExchangeEuronext Paris
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.